Description

This dual?action formulation combines entecavir and tenofovir—both potent nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)—to deliver synergistic viral suppression. The non?overlapping resistance profiles of these agents help reduce the risk of breakthrough and resistance, as observed in HBV clinical protocols. In HIV, this combination is used for pre?exposure prophylaxis (PrEP) in high?risk populations , offering robust antiviral action.

Entecavir & Tenofovir Tablets Product Specifications

Entecavir & Tenofovir Tablets Mechanism of Action

Entecavir (a guanosine analogue) and tenofovir (a nucleotide analogue) inhibit reverse transcriptase, blocking HBV DNA synthesis and, in HIV models, preventing viral replication. Combined therapy has demonstrated high viral suppression and reduced resistance. Tenofovir also forms part of oral PrEP regimens, significantly reducing HIV acquisition in high?risk groups.

Research Application Areas

• HBV studies: Viral load suppression, resistance development, combination therapy efficacy

• HIV research & PrEP modeling: Prophylaxis against infection in vitro/ex vivo

• Pharmacokinetics & drug–drug interaction analysis

• Resistance mutation selection and profiling assays

Safety & Handling

• Use lab-level PPE (gloves, glasses) and follow biosafety protocols.

• Administer orally to animal models per institutional guidelines.

• Store in a cool, dry place away from direct light.

• Dispose of per local chemical/biomedical waste policies.

Core Keywords

entecavir tenofovir tablets, HBV combo antiviral, tenofovir entecavir PrEP, H20203539, research-grade NRTI combo, HBV resistance study, HIV prevention research drug, wholesale antiviral tablets

Research Use Disclaimer

This product is for laboratory and preclinical research only, not for clinical, therapeutic, diagnostic, or veterinary use. Misuse may involve health, legal, or regulatory risks. Use under institutional protocols only.